- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05142150
Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE) (PEACE)
Palliation in Gynae-oncology: Patients Expectations and Assessment of Care
Study Overview
Detailed Description
Prospective observational cohort study.
Little is known about end of life care (EOL) in patients with ovarian or other gynaecological cancers. Patients typically have a high symptom burden and following several prior lines of therapy or the development of platinum resistant disease response rates to further active treatment are limited. Eliciting patients' values and preferences for end-of-life care and shared decision-making are central elements of patient-centered EOL care. The aim of this study is to assess the feasibility of collecting data on patient satisfaction towards end of life. Preliminary data on patient and carer satisfaction with care, the importance of aspects of care, as well as end of life treatment will also be collected. The study will also assess the carer satisfaction with care during bereavement and with the patient's dying experience.
The study will recruit beyond the targeted number of 73 patients number if the study is progressing favourably. Ideally, each patient will nominate a carer to also complete questionnaires and the carer will be able to assist in completing the diary, although this is not mandatory.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Kristina Lindemann, MD, PhD
- Phone Number: 004722934983
- Email: klinde@ous-hf.no
Study Contact Backup
- Name: Alice Bjørnlund-Larsen, MSc
- Phone Number: 004535453311
- Email: alice.bjoernlund-larsen@regionh.dk
Study Locations
-
-
-
Oslo, Norway, 0310
- Recruiting
- The Norwegian Radium Hospital
-
Contact:
- Kristina Lindemann, MD, PhD
- Phone Number: 5690 +47 22934000
- Email: klinde@ous-hf.no
-
Principal Investigator:
- Kristina Lindemann, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
A patient will be eligible for inclusion only if all of the following criteria are fulfilled:
- Patients with any advanced gynecological malignancy and a life expectancy of approximately 4 months as estimated by their treating physician*. Potential patient groups include, but are not limited to, those with platinum-resistant/refractory recurrent epithelial ovarian cancer (PRR-EOC), metastatic/recurrent cervical or endometrial cancer progressing after platinum-based chemotherapy; high grade/undifferentiated metastatic uterine sarcoma progressing after first-line chemotherapy etc.
- Patients may be on active cancer treatment, about to commence active cancer treatment or under observation/palliative care.
- Age ≥ 18 years
- Able (both physically and cognitively) to complete patient-reported outcome measures independently in languages that are available in this study (i.e. without assistance from hospital translator).
Exclusion Criteria:
A patient will not be eligible for inclusion if any of the following criteria are fulfilled:
- Unable to be comply with the protocol.
- A medical or psychological condition that limits the patient´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.
- Participation in another clinical trial.
A patient will be asked to appoint a carer.
Inclusion criteria carer:
- Age ≥ 18 years
- A relative or close friend who is actively supporting the patient in her illness
- Able (both physically and cognitively) to complete questionnaires independently in languages that are available in this study (i.e. without assistance from hospital translator).
Exclusion criteria carer
A carer will not be eligible for inclusion if any of the following criteria are fulfilled:
- Unable to be comply with the protocol
- A medical or psychological condition that limits the carer´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patient
Patient satisfaction with end of life care.
Questionnaire to be completed at baseline and every 8 week.
|
Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary. Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying. |
Carer
Carer satisfaction with care leading up to the time of death and the quality of the patient's death.
Questionnaire to be completed at baseline and every 8 weeks,and 5-7 weeks after patient deceased.
|
Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary. Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients who complete scheduled assessments with Canadian Health Care Evaluation Project (CANHELP) instrument, CANHELP Lite Individualised version
Time Frame: Within 42 days before their death
|
To study the feasibility of collecting data on patient satisfaction with care.
In all CANHELP Lite versions response options for each item range from 1'not at all satisfied' to 5 'completely satisfied'.
All versions have an overall satisfaction with care score, as well as scores on each of the individual domains.
All scores are re-scaled to range between 0 (worst possible value) to 100 (best possible value).
|
Within 42 days before their death
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of carers who complete scheduled assessments with Canadian Health Care Evaluation Project (CANHELP) Lite Individualized Caregiver
Time Frame: Within 42 days before patient's death
|
To study the feasibility of collecting data on carer satisfaction with care.
In all CANHELP Lite versions response options for each item range from 1'not at all satisfied' to 5 'completely satisfied'.
All versions have an overall satisfaction with care score, as well as scores on each of the individual domains.
All scores are re-scaled to range between 0 (worst possible value) to 100 (best possible value).
|
Within 42 days before patient's death
|
Number of carers who complete scheduled assessments with Canadian Health Care Evaluation Project (CANHELP) Lite bereavement and Quality of Death and Dying (QODD) questionnaire
Time Frame: Within 42 days of death up to 5-7 weeks after patient deceased.
|
To study the feasibility of collecting data on carer satisfaction with care leading up to the time of death and the quality of the patient´s death.
CANHELP response options range from 1'not at all satisfied' to 5 'completely satisfied', with an overall satisfaction with care score and scores on each individual domains.
All scores are re-scaled to range 0 (worst possible value) to 100 (best possible value).
The QODD questionnaire has 24 items that assess aspects of dying and death.
The QODD questionnaire contains 14 additional items that assess cargiver's demographic characteristics and relation to the deceased.
Response options for each item are rated on a scale from 0 (terrible) to 10 (almost perfect).
The items provide a single score, derived as a mean of the item values, transformed to a 0 to 100 scale.
|
Within 42 days of death up to 5-7 weeks after patient deceased.
|
Number of patients who received chemotherapy and other interventions as well as palliative care
Time Frame: Within 42 days before their death
|
To study use of chemotherapy, surgical interventions as well as palliative care involvement
|
Within 42 days before their death
|
Patient satisfaction with care
Time Frame: Baseline up to 5-7 weeks after patient deceased
|
Patient satisfaction will be assessed with CANHELP Lite Individualized.
In all CANHELP Lite versions response options for each item range from 1'not at all satisfied' to 5 'completely satisfied' .
A 'not applicable/not discussed' response option for items that patients/cares felt was not relevant to their situation.
All versions have an overall satisfaction with care score, as well as scores on each of the individual domains.
All scores are re-scaled to range between 0 (worst possible value) to 100 (best possible value).
The questionnaires will be administered and scored in accordance with the user manual.
|
Baseline up to 5-7 weeks after patient deceased
|
Carers satisfaction with care
Time Frame: Baseline up to 5-7 weeks after patient deceased
|
Satisfaction will be assessed with CANHELP Lite bereavement and quality of death and dying (QODD) questionnaire. The QODD questionnaire has 24 items that assess various aspects of dying and death including whether the patient's symptoms were adequately controlled, whether dignity was maintained, time spent with loved ones in days leading up to death and whether the patient's wishes were adhered to. The QODD questionnaire also contains 14 additional items that assess the cargiver's demographic characteristics and relation to the deceased. The response options for each item are rated on a scale from 0 (terrible) to 10 (almost perfect). The items provide a single score, derived as a mean of the item values, transformed to a 0 to 100 scale. |
Baseline up to 5-7 weeks after patient deceased
|
The importance of aspects of care for patients
Time Frame: Baseline up to 5-7 weeks after patient deceased
|
Importance of aspects of care will be assessed through CANHELP Lite.
|
Baseline up to 5-7 weeks after patient deceased
|
The importance of aspects of care for carers
Time Frame: Baseline up to 5-7 weeks after patient deceased
|
Importance of aspects of care assessed through CANHELP Lite.
|
Baseline up to 5-7 weeks after patient deceased
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GCIG SB-001/NSGO-CTU-PEACE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynaecological Cancer
-
NHS GrampianRecruitingGynaecological CancerUnited Kingdom
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Hospital Universitario 12 de OctubreNot yet recruitingQuality of Life | Sexual Dysfunction | Lymphedema, Lower Limb | Gynaecological Cancer
-
University Hospital, Basel, SwitzerlandRecruiting
-
Fevzi ShakirUnknownHeated Humidified Carbon Dioxide in Gynaecological Laparoscopic SurgeryUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedGynaecological Malignant Tumours With Indication of Pelvic LymphadenectomyFrance
-
Royal Marsden NHS Foundation TrustCompletedGynaecological, Urological or Rectal Cancer
-
Assistance Publique - Hôpitaux de ParisCompletedGYNAECOLOGICAL INFECTIONFrance
-
Institute of Cancer Research, United KingdomAstraZeneca; Cancer Research UKRecruitingGynaecological CancersUnited Kingdom
-
Hospices Civils de LyonCompletedHead and Neck Cancer | Digestive Cancer | Gynaecological CancerFrance
Clinical Trials on Questionaire
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; University of ChicagoRecruitingBladder Cancer | Urothelial Cancer | Ureter Cancer | Renal Pelvis CancerUnited States
-
Sygehus LillebaeltKolding SygehusCompleted
-
University Hospital Inselspital, BerneCompletedSexual Orientation | Family CharacteristicsSwitzerland
-
Fayoum UniversityCompleted
-
The Cleveland ClinicUnknownSleep Apnea | Adverse EventUnited States
-
Hospices Civils de LyonCompletedAnoxic-Ischemic EncephalopathyFrance
-
Hillel Yaffe Medical CenterCompletedConditions Influencing Health StatusIsrael
-
Eurofertil IVF Health CenterCompletedStress | PregnancyTurkey
-
Zurich University of Applied SciencesCompleted